# Axel Hauschild

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/axel-hauschild/

## Facts

| Field | Value |
| --- | --- |
| Citations | 73,993 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 112 |
| i10-index | 416 |
| Last Known Institution | University Hospital Schleswig-Holstein |
| OpenAlex ID | https://openalex.org/A5044736874 |
| ORCID iD | https://orcid.org/0000-0002-1212-9587 |
| Works | 813 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma](https://scholariq.org/papers/efficacy-and-safety-of-vismodegib-in-advanced-basal-cell-carcinoma/)
- [Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines](https://scholariq.org/papers/diagnosis-and-treatment-of-basal-cell-carcinoma-european-consensus-based/)
- [Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016](https://scholariq.org/papers/diagnosis-and-treatment-of-melanoma-european-consensus-based-interdisciplinary/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment](https://scholariq.org/papers/european-interdisciplinary-guideline-on-invasive-squamous-cell-carcinoma-of-the/)
- [European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023](https://scholariq.org/papers/european-consensus-based-interdisciplinary-guideline-for-diagnosis-and-treatment/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [University Hospital Schleswig-Holstein](https://scholariq.org/institutions/university-hospital-schleswig-holstein/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.